FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

UniQure needs to run another study to prove its gene therapy "actually helps people with Huntington's disease," a senior FDA official said. The official said UniQure is the "latest company to make a failed therapy for Huntington's patients.

CNBC • 20 hours ago

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

A senior ​FDA ‌official called Uniqure's ​experimental ​Huntington's disease ⁠treatment ​a "failed product" ​in a conference ​call ​with media members ‌on ⁠Thursday, casting further ​doubt ​on ⁠the prospects ​of ​its ⁠experimental gene ⁠therapy.

Reuters • 21 hours ago

FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial

An official from the U.S. Food and Drug Administration (FDA) defended the agency's request for a new placebo-controlled study for uniQure N.V.'s (NASDAQ: QURE) experimental gene therapy for Huntington's disease.

Benzinga • a day ago

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, March 5, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Company") (NASDAQ: QURE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

PRNewsWire • Mar 5, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).

PRNewsWire • 17 hours ago

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.

GlobeNewsWire • a day ago

Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class Action

ATLANTA, March 05, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding uniQure's business, operations, and prospects, including allegations that: (1) the design of uniQure's Pivotal Study—including comparison of the Pivotal Study results to the ENROLL-HD external historical data set—was not fully approved by the FDA; and (2) Defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application (“BLA”) timeline to perform additional studies to supplement its BLA submission.

GlobeNewsWire • 18 hours ago

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK, March 5, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period").

PRNewsWire • Mar 5, 2026

QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in uniQure between September 24, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK, March 5, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against uniQure N.V.

PRNewsWire • Mar 5, 2026

UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V.

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

GlobeNewsWire • Mar 5, 2026